Skip to Main Content

Paper Details

Targeting RET Kinase in Neuroendocrine Prostate Cancer.
Mol Cancer Res
26
2020
AR, AR-dependent prostate cancer cell lines, AR-independent, AR-independent cell lines, AVPC, NEPC, NEPC patient-derived xenografts, NEPC tumors, Neuroendocrine Prostate Cancer, RET, RET Kinase, RET kinase, RET transcript, aggressive variant prostate cancer (AVPC) tumors, androgen, androgen receptor, human, mCRPC, metastatic castration-resistant prostate cancer, mouse, neuroendocrine prostate cancer, patient, patients, prostate cancer, tumor, tumors
Author NameAffiliation
Anjali V SheahanDana-Farber Cancer Institute
Ilsa ColemanFred Hutchinson Cancer Research Center
Owen N WitteUniversity of California-Los Angeles
Colm MorrisseyUniversity of Washington
Eva CoreyUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Leigh EllisDana-Farber Cancer Institute
Leigh EllisBroad Institute of Harvard and MIT
  • 1 - 11

Datasets

Release 1.2